Departamento de Bioquímica-Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, CP: 486, CEP: 31270-901, Belo Horizonte, MG, Brazil.
Vaccine. 2013 Jun 7;31(25):2749-55. doi: 10.1016/j.vaccine.2013.03.048. Epub 2013 May 7.
A chimeric protein was constructed expressing three epitopes of LiD1, a dermonecrotic toxin from the venom of Loxosceles intermedia spider. This species is responsible for a large number of accidents involving spiders in Brazil. We demonstrated that the chimeric protein (rCpLi) generated is atoxic and that antibodies previously developed in rabbits against synthetic epitopes reactive with rCpLi in ELISA and immunoblot assays. The antibody response in rabbits against the rCpLi was evaluated by ELISA and we have detected an antibody response in all immunized animals. Overlapping peptides covering the amino acid sequence of the rCpLi were synthesized on a cellulose membrane, and their recognition by rabbit anti-rCpLi serum assessed. Three different antigenic regions were identified. The percentage of inhibition of the dermonecrotic, hemorrhagic and edematogenic activities caused by the recombinant protein LiD1r in naïve rabbits was assessed by pre-incubation with anti-rCpLi antibodies. Anti-rCpLi induced good dermonecrotic and hemorrhagic protection. The levels of protection were similar to the antiboides anti-LiD1r. In summary, we have developed a polyepitope recombinant chimeric protein capable of inducing multiple responses of neutralizing antibodies in a rabbit model. This engineered protein may be a promising candidate for therapeutic serum development or vaccination.
构建了表达 LiD1 三个表位的嵌合蛋白,LiD1 是来自中间 Loxosceles intermedia 蜘蛛毒液的一种皮肤坏死毒素。这种蜘蛛在巴西造成了大量的蜘蛛咬伤事故。我们证明了所产生的嵌合蛋白(rCpLi)是无毒的,并且先前在兔子中针对与 ELISA 和免疫印迹分析中的 rCpLi 反应的合成表位产生的抗体。通过 ELISA 评估了兔子针对 rCpLi 的抗体反应,我们在所有免疫动物中均检测到了抗体反应。在纤维素膜上合成了覆盖 rCpLi 氨基酸序列的重叠肽,并评估了兔抗 rCpLi 血清对其的识别。鉴定出了三个不同的抗原区域。通过用抗 rCpLi 抗体预先孵育,评估了重组蛋白 LiD1r 在未致敏兔子中引起的皮肤坏死、出血和水肿活性的抑制百分比。抗 rCpLi 诱导了良好的皮肤坏死和出血保护。保护水平与抗 LiD1r 抗体相似。总之,我们开发了一种多表位重组嵌合蛋白,能够在兔子模型中诱导多种中和抗体反应。这种工程蛋白可能是治疗血清开发或疫苗接种的有前途的候选物。